Morgan Stanley Maintains Overweight on Silence Therapeutics, Lowers Price Target to $25

Benzinga · 5d ago
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and lowers the price target from $45 to $25.